Products

API’s		Category	Specifications	Regulatory Status
	Atenolol	Anti-Hypertensive	IP/BP/EP/USP	CEP, EU GMP
	Amlodipine Besylate	Anti-Hypertensive	IP/BP/EP/USP	DMF Available
	Metoprolol Succinate	Anti-Hypertensive	IP/BP/EP/USP	DMF Available
	Metoprolol Tartrate	Anti-Hypertensive	IP/BP/EP/USP	DMF Available
	Roxithromycin	Macrolides	IP/BP/EP	CEP, KFDA
	Azithromycin	Macrolides	IP/BP/EP/USP	CEP
	Clarithromycin Granules 27.5%	Macrolides	In-House	DMF Available
	Clarithromycin Granules 33%	Macrolides	In-House
	Clarithromycin Granules 43%	Macrolides	In-House	DMF Available
	Pregabalin	Neuromodulator	IP/EP/In-House	EU DMF available and CEP applied
	Ceftriaxone Sodium	Sterile Cephalosporins	IP/BP/EP/USP	DMF Available
	Cefotaxime Sodium	Sterile Cephalosporins	IP/BP/EP/USP	DMF Available
	Cefepime (with L-Arginine) for Injection	Sterile Cephalosporins	IP/USP
	Meropenem (with Sodium Carbonate) for Injection	Carbapenems	IP/USP	DMF Available
	Doripenem	Carbapenems	In-House	DMF Available
	Biapenem	Carbapenems	In-House	DMF Available
	Tebipenem	Carbapenems	In-House
	Lymecycline	Anti-Acne, Anti-Infective	EP	DMF Available
	Nitroxoline	Urological	In-House	DMF Available

Products under development

API’s	Category	R&D Sample availability	R&D Tech pack	Specifications
Ticagrelor	Anti-Thrombotic	Available	Apr.2020	IP/ In-House
Apixaban	Anti-Thrombotic	Available	Available	In-House
Rivaroxaban	Anti-Thrombotic	Available	Available	In-House
Canagliflozin	Anti-Diabetic	Available	Sep. 2020	In-House
Dapagliflozin	Anti-Diabetic	Available	Apr.2020	In-House
Empagliflozin	Anti-Diabetic	Available	Jun.2020	In-House
Imipenem (Non-Sterile)	Carbapenems	Available	Jun.2020	USP
Ertapenem	Carbapenems	Jun.2020	Apr.2020	In-House
Faropenem	Carbapenems	Available	Oct. 2019	In-House
Ceftaroline Fosamil	Sterile Cephalosporins	Apr.2020	Aug.2020	In-House